Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Histology and Histopathology|March 26, 2024
Upregulation and epigenetic modification of the creatine transporter SLC6A8 in non-small cell lung cancerChristiane Kuempers, Karoline Schnepf, Sebastian Marwitz, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinomaRichard Riedel, Sebastian Michels, Carina Heydt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 9, 2016
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasAndreas H Scheel, Manfred Dietel, Lukas C Heukamp, et al.
Oncoimmunology|July 29, 2016
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterationsAndreas H Scheel, Sascha Ansén, Anne M Schultheis, et al.
Journal of Leukocyte Biology|August 19, 2016
Antigen-presenting human B cells are expanded in inflammatory conditionsAlexander Shimabukuro-Vornhagen, María García-Márquez, Rieke N Fischer, et al.
JTO Clinical and Research Reports|March 12, 2026
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET InhibitionRichard Riedel, Lea Ruge, Malte Verheyen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Cancer Medicine|May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessmentLucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Nature Communications|November 9, 2018
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Pageof 2